These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Design and identification of a new farnesoid X receptor (FXR) partial agonist by computational structure-activity relationship analysis: Ligand-induced H8 helix fluctuation in the ligand-binding domain of FXR may lead to partial agonism. Gohda K; Iguchi Y; Masuda A; Fujimori K; Yamashita Y; Teno N Bioorg Med Chem Lett; 2021 Jun; 41():128026. PubMed ID: 33839252 [TBL] [Abstract][Full Text] [Related]
24. Design, synthesis, and biological evaluation of novel FXR agonists based on auraptene. Qiu Q; Wang Y; Gu G; Yu F; Zhang S; Zhao Y; Ling B Bioorg Chem; 2021 Oct; 115():105198. PubMed ID: 34333419 [TBL] [Abstract][Full Text] [Related]
25. Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH). Tully DC; Rucker PV; Chianelli D; Williams J; Vidal A; Alper PB; Mutnick D; Bursulaya B; Schmeits J; Wu X; Bao D; Zoll J; Kim Y; Groessl T; McNamara P; Seidel HM; Molteni V; Liu B; Phimister A; Joseph SB; Laffitte B J Med Chem; 2017 Dec; 60(24):9960-9973. PubMed ID: 29148806 [TBL] [Abstract][Full Text] [Related]
26. Discovery of novel ketoxime ether derivatives with potent FXR agonistic activity, oral effectiveness and high liver/blood ratio. Tang X; Ning M; Ye Y; Gu Y; Yan H; Leng Y; Shen J Bioorg Med Chem; 2021 Aug; 43():116280. PubMed ID: 34256254 [TBL] [Abstract][Full Text] [Related]
27. Proglumide Reverses Nonalcoholic Steatohepatitis by Interaction with the Farnesoid X Receptor and Altering the Microbiome. Gay MD; Cao H; Shivapurkar N; Dakshanamurthy S; Kallakury B; Tucker RD; Kwagyan J; Smith JP Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163821 [TBL] [Abstract][Full Text] [Related]
28. N Masuda A; Gohda K; Iguchi Y; Fujimori K; Yamashita Y; Oda K; Une M; Teno N Bioorg Med Chem; 2020 Jul; 28(14):115512. PubMed ID: 32616182 [TBL] [Abstract][Full Text] [Related]
30. Extending the structure-activity relationship of anthranilic acid derivatives as farnesoid X receptor modulators: development of a highly potent partial farnesoid X receptor agonist. Merk D; Lamers C; Ahmad K; Carrasco Gomez R; Schneider G; Steinhilber D; Schubert-Zsilavecz M J Med Chem; 2014 Oct; 57(19):8035-55. PubMed ID: 25255039 [TBL] [Abstract][Full Text] [Related]
31. On the relationship of anthranilic derivatives structure and the FXR (Farnesoid X receptor) agonist activity. Kronenberger T; Windshügel B; Wrenger C; Honorio KM; Maltarollo VG J Biomol Struct Dyn; 2018 Dec; 36(16):4378-4391. PubMed ID: 29237358 [TBL] [Abstract][Full Text] [Related]
32. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH). Fiorucci S; Biagioli M; Sepe V; Zampella A; Distrutti E Expert Opin Investig Drugs; 2020 Jun; 29(6):623-632. PubMed ID: 32552182 [TBL] [Abstract][Full Text] [Related]
33. Novel substituted isoxazole FXR agonists with cyclopropyl, hydroxycyclobutyl and hydroxyazetidinyl linkers: Understanding and improving key determinants of pharmacological properties. Kinzel O; Steeneck C; Schlüter T; Schulz A; Gege C; Hahn U; Hambruch E; Hornberger M; Spalwisz A; Frick K; Perović-Ottstadt S; Deuschle U; Burnet M; Kremoser C Bioorg Med Chem Lett; 2016 Aug; 26(15):3746-53. PubMed ID: 27268696 [TBL] [Abstract][Full Text] [Related]
34. Cycloastragenol improves hepatic steatosis by activating farnesoid X receptor signalling. Gu M; Zhang S; Zhao Y; Huang J; Wang Y; Li Y; Fan S; Yang L; Ji G; Tong Q; Huang C Pharmacol Res; 2017 Jul; 121():22-32. PubMed ID: 28428116 [TBL] [Abstract][Full Text] [Related]
35. Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis. Chianelli D; Rucker PV; Roland J; Tully DC; Nelson J; Liu X; Bursulaya B; Hernandez ED; Wu J; Prashad M; Schlama T; Liu Y; Chu A; Schmeits J; Huang DJ; Hill R; Bao D; Zoll J; Kim Y; Groessl T; McNamara P; Liu B; Richmond W; Sancho-Martinez I; Phimister A; Seidel HM; Badman MK; Joseph SB; Laffitte B; Molteni V J Med Chem; 2020 Apr; 63(8):3868-3880. PubMed ID: 31940200 [TBL] [Abstract][Full Text] [Related]
36. Nonsteroidal FXR Ligands: Current Status and Clinical Applications. Gege C; Hambruch E; Hambruch N; Kinzel O; Kremoser C Handb Exp Pharmacol; 2019; 256():167-205. PubMed ID: 31197565 [TBL] [Abstract][Full Text] [Related]
37. Multi-model in silico characterization of 3-benzamidobenzoic acid derivatives as partial agonists of Farnesoid X receptor in the management of NAFLD. Mitra S; Halder AK; Ghosh N; Mandal SC; Cordeiro MNDS Comput Biol Med; 2023 May; 157():106789. PubMed ID: 36963353 [TBL] [Abstract][Full Text] [Related]
38. Synthesis and biological evaluation of novel SIPI-7623 derivatives as farnesoid X receptor (FXR) antagonists. Nian SY; Wang GP; Jiang ZL; Xiao Y; Huang MH; Zhou YH; Tan XD Mol Divers; 2019 Feb; 23(1):19-33. PubMed ID: 29974364 [TBL] [Abstract][Full Text] [Related]
39. Pose Filter-Based Ensemble Learning Enables Discovery of Orally Active, Nonsteroidal Farnesoid X Receptor Agonists. Xia J; Wang Z; Huan Y; Xue W; Wang X; Wang Y; Liu Z; Hsieh JH; Zhang L; Wu S; Shen Z; Zhang H; Wang XS J Chem Inf Model; 2020 Mar; 60(3):1202-1214. PubMed ID: 32050066 [TBL] [Abstract][Full Text] [Related]
40. Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis. Zhang C; Liu Y; Wang Y; Ge X; Jiao T; Yin J; Wang K; Li C; Guo S; Xie X; Xie C; Nan F J Med Chem; 2022 Oct; 65(19):13452-13472. PubMed ID: 36107013 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]